Company profile
INSMED Inc
NASDAQ:INSMBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Amikacin Sulfate | approved | — | 0 | — |
| BRENSOCATIB | approved | — | 15 | approved |
| MECASERMIN RINFABATE | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (48)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05673603 | phase1 | completed | 2021-07-20 | 2023-02-14 | Insmed Incorporated | A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment |
| NCT04791514 | phase2 | terminated | 2022-03-29 | 2022-08-26 | Insmed Incorporated | A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) |
| NCT05652257 | phase1 | completed | 2021-08-13 | 2021-09-14 | Insmed Incorporated | A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants |
| NCT06685835 | phase2 | terminated | 2024-12-16 | 2026-02-12 | Insmed Incorporated | A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) |
| NCT06013241 | phase2 | completed | 2023-10-30 | 2025-09-30 | Insmed Incorporated | A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) |
FDA applications (3)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 021884 | BLA | Insmed Incorporated | ||||
Loading… | ||||||
| NDA 207356 | NDA | INSMED INC | ||||
Loading… | ||||||
| NDA 217673 | NDA | INSMED INC | ||||
Loading… | ||||||